Yes. Long-term care residents with atrial fibrillation and no absolute contraindications to oral anticoagulation are, as a group, undertreated. Most should benefit from anticoagulation.
s EPIDEMIOLOGY Nonvalvular atrial fibrillation, the most common arrhythmia in older people, was present in 6.2% of men and 4.8% of women who were 65 years old and over and living in the community at baseline in the Cardiovascular Health Study. 1 The prevalence of atrial fibrillation in long-term care residents is higher, 7.5% to 17%, 2-4 reflecting the higher age and increased prevalence of cardiovascular disease in long-term care residents compared with adults in the community.
In the Framingham study, 5 approximately 20% of ischemic strokes were attributed to cardioembolic events resulting from atrial fibrillation. Compared with other ischemic strokes, strokes associated with atrial fibrillation carried a mortality risk approximately twice as high and conferred more severe functional deficits in survivors.
s ANTICOAGULATION REDUCES STROKES BUT INCREASES BLEEDING
A pooled analysis of five major trials in community-dwelling elderly patients with atrial fibrillation 6 demonstrated that oral anticoagulation significantly reduces the risk of stroke.
Adjusted-dose warfarin therapy reduced the risk of stroke by 51% in adults older than 75 years without risk factors, and by 85% in those with one or more risk factors. Aspirin was less effective than warfarin but better than placebo.
Studies did not demonstrate a role for fixed-dose warfarin plus aspirin-this combination is less effective than adjusted-dose oral anticoagulation and causes more adverse effects.
A recent meta-analysis 7 demonstrated that treating 1,000 patients who had atrial fibrillation for 1 year with warfarin vs aspirin prevented 23 ischemic strokes but caused 9 additional major bleeds, with survival benefit apparent 3 years after starting therapy. The number needed to treat varied from 17 in patients with prior cerebrovascular disease to 83 in those without.
After major study results were published in the 1990s, the rate of use of oral anticoagulation of older adults with atrial fibrillation in the community increased, from approximately 13% to 50%. 8 Trends in oral anticoagulation in the long-term care setting have not been studied as much as in the community. Recent cross-sectional studies indicate warfarin is offered to 20% to 53% of long-term care residents with atrial fibrillation who do not have contraindications to it. [2] [3] [4] Only about 40% of patients in nursing homes who receive warfarin achieve a therapeutic international normalized ratio (INR), however, compared with 50% in the community and 70% to 80% in anticoagulation trials. 9 A clear understanding of stroke risk stratification may help balance the benefits of anticoagulation with the bleeding risks in nursing home residents.
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The yearly risk for stroke in communitydwelling people with atrial fibrillation is about 5%, varying from less than 1% in young people without risk factors to 17.6% in people with two or three risk factors. 10 Long-term care residents with atrial fibrillation are older and have more cardiovascular disease than adults in the community. Thus they are more likely to fall into the moderate-risk or highrisk categories.
Guidelines derived from outpatient studies of atrial fibrillation in persons of all ages, published by the American College of Chest Physicians in 2001, 11, 12 can be used to divide persons with atrial fibrillation into three risk groups (TABLE 1) . People who are 75 years old or older are classified as high-risk by this stratification.
Another risk-stratification scheme, called "CHADS 2 , may better reflect the frail elders seen in long-term care (TABLE 2). 13 Validated in a cohort aged 65 to 95 years who were recently discharged from a hospital, this scheme may be particularly useful for people at low risk for whom anticoagulation and its attendant risk of bleeding may be deferred.
A similar scoring system based on the Framingham population was also published recently (TABLE 3) . 14 Naturally, any stratification scheme may underestimate stroke risk in certain people at high risk, such as those with recent transient ischemic attack, uncontrolled hypertension, cardiac thrombus, or mitral stenosis. The most useful strategy in deciding whether to initiate, continue, or withhold oral anticoagulation may be to complement the risk strat- Leukoaraiosis seen on computed tomography was an independent risk factor for intracranial hemorrhage in the Stroke Prevention in Reversible Ischemia Trial (SPIRIT) (hazard ratio 7.5, 95% confidence interval 3.4-16), 16 and may be common in persons with dementia and vascular risks often seen in the long-term care setting.
Other risk factors for bleeding such as hypertension, cerebrovascular disease, renal disease, alcoholism, or liver disease have been identified in some studies but not all. Even the bleeding risks associated with falls in older adults may not outweigh the benefits of anticoagulation. 17 The studies of oral anticoagulation are difficult to interpret because of methodological differences, including intensity of anticoagulant therapy in different studies.
Other potential risk factors for bleeding in older adults include increased sensitivity of older adults to warfarin, polypharmacy, probable underestimation of adverse drug events in the long-term care population, increased risk of injury from falls because of osteoporosis, and other associated comorbidities such as dementia.
One way of balancing the risk of bleeding for a long-term care resident is to determine if his or her risk is low, intermediate, or prohibitive ( 18, 19 Major predicting factors include age > 65 years, history of stroke, gastrointestinal bleeding, myocardial infarction, anemia, renal dysfunction, and diabetes mellitus. 18 Since few adults over 80 years of age were included in the research cohorts, caution is necessary in applying these schemes to the long-term care setting.
One further factor to consider is the patient's perception of risk. Patients perceive stroke as a more serious outcome than bleeding and may be more willing to take oral anticoagulation despite the risk of bleeding. 20 At this time there is no comparable alternative to warfarin to optimally reduce stroke risk while limiting bleeding risk in older adults with atrial fibrillation. Clinical studies of combined platelet inhibitors in vascular disease and acute coronary syndromes have been published, 21, 22 but not specifically in the setting of atrial fibrillation. Future studies would be helpful to address the benefit and risk of combined antiplatelet therapy or other therapy such as a direct thrombin inhibition with ximelaga- cardioembolic stroke or to acquiring functional deficits that make them more dependent and lower their quality of life.
s RECOMMENDATIONS
• Consider adjusted-dose warfarin for longterm care residents with atrial fibrillation as per the American College of Chest Physicians recommendations. The target INR is 2 to 3.
• The decision to start warfarin is based on the individual's risks and potential benefits. The patient's preferences and those of his or her family should be considered.
• The optimal intensity of anticoagulation is unknown for subgroups of patients with atrial fibrillation who have at least an intermediate risk of bleeding (eg, adults older than 75 or 80 years), but there is no evidence that an INR lower than 2 is efficacious. Some recommend an INR of 2 to 2.5 instead of 2 to 3. Another option is to use aspirin instead of warfarin for patients at high risk of bleeding. 
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